232 related articles for article (PubMed ID: 31370815)
1. Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study.
Tanaka T; Sato T; Nishiofuku H; Masada T; Tatsumoto S; Marugami N; Otsuji T; Kanno M; Koyama F; Sho M; Kichikawa K
BMC Cancer; 2019 Aug; 19(1):758. PubMed ID: 31370815
[TBL] [Abstract][Full Text] [Related]
2. Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population.
Huppert P; Wenzel T; Wietholtz H
Cardiovasc Intervent Radiol; 2014 Feb; 37(1):154-64. PubMed ID: 23670568
[TBL] [Abstract][Full Text] [Related]
3. Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.
Pernot S; Artru P; Mithieux F; Marsot J; Watkin E; Pellerin O; Lledo G; Chalabreysse P; Desramé J; Taieb J
Clin Res Hepatol Gastroenterol; 2015 Dec; 39(6):e73-7. PubMed ID: 26141343
[TBL] [Abstract][Full Text] [Related]
4. Transcatheter arterial chemoembolization with docetaxel-loaded microspheres controls heavily pretreated unresectable liver metastases from colorectal cancer: a case study.
Seki A; Hori S
Int J Clin Oncol; 2011 Oct; 16(5):613-6. PubMed ID: 21249412
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan-Eluting 75-150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study.
Fereydooni A; Letzen B; Ghani MA; Miszczuk MA; Huber S; Chapiro J; Schlachter T; Geschwind JF; Georgiades C
J Vasc Interv Radiol; 2018 Dec; 29(12):1646-1653.e5. PubMed ID: 30337148
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.
Martin RC; Scoggins CR; Tomalty D; Schreeder M; Metzger T; Tatum C; Sharma V
J Gastrointest Surg; 2012 Aug; 16(8):1531-8. PubMed ID: 22528576
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report.
Martin RC; Robbins K; Tomalty D; O'Hara R; Bosnjakovic P; Padr R; Rocek M; Slauf F; Scupchenko A; Tatum C
World J Surg Oncol; 2009 Nov; 7():80. PubMed ID: 19886993
[TBL] [Abstract][Full Text] [Related]
8. The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis.
Pereira PL; Iezzi R; Manfredi R; Carchesio F; Bánsághi Z; Brountzos E; Spiliopoulos S; Echevarria-Uraga JJ; Gonçalves B; Inchingolo R; Nardella M; Pellerin O; Sousa M; Arnold D; de Baère T; Gomez F; Helmberger T; Maleux G; Prenen H; Sangro B; Zeka B; Kaufmann N; Taieb J
Cardiovasc Intervent Radiol; 2021 Jan; 44(1):50-62. PubMed ID: 32974773
[TBL] [Abstract][Full Text] [Related]
9. Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure: results of a phase I/II study.
Nishiofuku H; Tanaka T; Matsuoka M; Otsuji T; Anai H; Sueyoshi S; Inaba Y; Koyama F; Sho M; Nakajima Y; Kichikawa K
J Vasc Interv Radiol; 2013 Jan; 24(1):56-65. PubMed ID: 23194749
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.
Richardson AJ; Laurence JM; Lam VW
J Vasc Interv Radiol; 2013 Aug; 24(8):1209-17. PubMed ID: 23885916
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases.
Sljivic M; Sever M; Ocvirk J; Mesti T; Brecelj E; Popovic P
Radiol Oncol; 2024 Jun; 58(2):214-220. PubMed ID: 38553252
[TBL] [Abstract][Full Text] [Related]
12. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.
Aranda E; Valladares M; Martinez-Villacampa M; Benavides M; Gomez A; Massutti B; Marcuello E; Constenla M; Cámara JC; Carrato A; Dueñas R; Reboredo M; Navarro M; Díaz-Rubio E
Ann Oncol; 2009 Feb; 20(2):251-7. PubMed ID: 18718892
[TBL] [Abstract][Full Text] [Related]
13. FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience.
Kim JH; Park SJ; Park MI; Moon W; Kim SE; Ku KH; Song SE; Kim JH
Korean J Gastroenterol; 2014 Jan; 63(1):18-24. PubMed ID: 24463284
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.
Miller CL; Taylor MS; Qadan M; Deshpande V; Worthington S; Smalley R; Collura C; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Parikh AR; Berger D; Tanabe KK; Lillemoe KD; Ferrone CR
J Gastrointest Surg; 2017 Nov; 21(11):1831-1840. PubMed ID: 28884391
[TBL] [Abstract][Full Text] [Related]
15. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen.
Deyme L; Barbolosi D; Mbatchi LC; Tubiana-Mathieu N; Ychou M; Evrard A; Gattacceca F
Cancer Chemother Pharmacol; 2021 Aug; 88(2):247-258. PubMed ID: 33912999
[TBL] [Abstract][Full Text] [Related]
18. Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors.
Poggi G; Quaretti P; Minoia C; Bernardo G; Bonora MR; Gaggeri R; Ronchi A; Saluzzo CM; Azzaretti A; Rodolico G; Montagna M; Amatu A; Teragni C; Palumbo I; Traverso E; Tonini S; Villani L; Scelsi M; Baiardi P; Felisi MG; Sottotetti F; Tagliaferri B; Riccardi A
Anticancer Res; 2008; 28(6B):3835-42. PubMed ID: 19192637
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer.
Hsu HC; Chou WC; Shen WC; Wu CE; Chen JS; Liau CT; Lin YC; Yang TS
Anticancer Res; 2013 Aug; 33(8):3317-25. PubMed ID: 23898098
[TBL] [Abstract][Full Text] [Related]
20. PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer.
Jones RP; Malik HZ; Fenwick SW; Terlizzo M; O'Grady E; Stremitzer S; Gruenberger T; Rees M; Plant G; Figueras J; Albiol M; Adam R; Awad S; Poston GJ
Eur J Surg Oncol; 2016 Dec; 42(12):1866-1872. PubMed ID: 27561844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
